Lancet Diabetes & Endocrinology editorial questions pace of GLP-1 use
A journal editorial argues that GLP-1 use has grown faster than the safety data and monitoring around it, though it offers no new risk numbers for US patients.
The Lancet Diabetes & Endocrinology has published an editorial titled "Soaring GLP-1 receptor agonist use," arguing that the growth of this drug class has outpaced the systems meant to guide and monitor it [1]. The piece raises concerns in three areas: equity of access, use outside regular clinical monitoring, and how thin the long-term safety data is relative to the number of people now exposed to the drugs [1].
An editorial states a journal's position. It is not a new study, and it does not present new patient data or new trial results [1]. GLP-1 receptor agonists [1] are the class that includes semaglutide (sold as Ozempic, Wegovy and Rybelsus) and tirzepatide (sold as Mounjaro and Zepbound).
The editorial does not put a number on how many people worldwide take these drugs, does not give a growth rate, and does not name a specific safety signal it considers newly established [1]. It describes a mismatch of scale rather than a newly identified harm [1].
On access, the editorial frames the issue as one of equity — essentially, who is able to get a GLP-1 receptor agonist and who is not [1]. It does not break that question down by country, insurance status or income, and it does not discuss US coverage rules, prices or prior authorization [1].
On monitoring, the editorial points to use that happens outside the kind of structured follow-up that occurs in a clinical trial or a formal treatment program [1]. It does not say how common unmonitored use is, or what share of people taking the drugs fall into that category [1].
On long-term safety, the editorial says the available data is thin compared with the size of the exposed population [1]. It does not state how many years of data exist, how many people have been followed for how long, or which specific long-term risks remain uncertain [1].
Why it matters for patients
For someone taking semaglutide or tirzepatide, the editorial's main point is about a gap: the drugs are used far more widely than they have been studied over the long run [1]. It is a call for attention, not a finding that the drugs are unsafe; the editorial does not report a new side effect or a new risk estimate [1].
The monitoring concern is something patients can check against their own care. The editorial does not say what follow-up should consist of, how often people should be seen, or what tests should be done, and it makes no recommendations about testing or dose changes [1].
The access concern is about who can obtain treatment in the first place [1]. Whether that concern applies to any particular US insurance plan or patient group has not been reported [1].
The editorial also does not distinguish between people taking these drugs for type 2 diabetes, for obesity or for other reasons, and it does not separate semaglutide from tirzepatide in its discussion [1]. Any differences in how the concerns apply across those groups are not addressed in it [1].
What is not yet known
No user count, growth rate, list of specific long-term risks, or set of clinical recommendations appears in the editorial [1]. Whether the journal plans follow-up work, and whether regulators or medical societies will respond with new guidance, has not been reported [1].
Sources
Semaglutides.org provides information only, not medical advice. Talk to a licensed provider about your own care before making changes. Some telehealth links are affiliate links and are labeled where they appear.